Tick-borne encephalitis

From Wikipedia, the free encyclopedia
  (Redirected from Tickborne Encephalitis)
Jump to navigation Jump to search
Tick-borne meningoencephalitis
EurAsia TBE-belt.svg
Infected countries/areas in Eurasia
SpecialtyInfectious disease

Tick-borne encephalitis (TBE) is a viral infectious disease involving the central nervous system. The disease most often manifests as meningitis, encephalitis, or meningoencephalitis. Long-lasting or permanent neuropsychiatric consequences are observed in 10 to 20% of infected patients.

The number of reported cases has been increasing in most countries.[1] TBE is posing a concerning health challenge to Europe, as the number of reported human cases of TBE in all endemic regions of Europe have increased by almost 400% within the last three decades.[2]

The tick-borne encephalitis virus is known to infect a range of hosts including ruminants, birds, rodents, carnivores, horses, and humans. The disease can also be spread from animals to humans, with ruminants and dogs providing the principal source of infection for humans.[3]

Signs and symptoms[edit]

Symptoms of TBE-infection

The disease typically follows a biphasic pattern in 72–87% of patients and the median incubation period is 8 days (range, 4–28 days) after tick bite. Non-specific symptoms of mild fever, malaise, headache, nausea, vomiting and myalgias may be present as first manifestation of the disease and spontaneously resolve within 1 week. After another week the patient may develop neurological symptoms.[4] The virus can result in long neurological symptoms, infecting the brain (encephalitis), the meninges (meningitis) or both (meningoencephalitis).[5] In general, mortality is 1% to 2%, with deaths occurring 5 to 7 days after the onset of neurologic signs.

In dogs, the disease also manifests as a neurological disorder with signs varying from tremors to seizures and death.[3]

In ruminants, neurological disease is also present, and animals may refuse to eat, appear lethargic, and also develop respiratory signs.[3]


TBE is caused by tick-borne encephalitis virus, a member of the genus Flavivirus in the family Flaviviridae. It was first isolated in 1937. Three virus sub-types also exist: European or Western tick-borne encephalitis virus (transmitted by Ixodes ricinus), Siberian tick-borne encephalitis virus (transmitted by I. persulcatus), and Far-Eastern tick-borne encephalitis virus, formerly known as Russian spring summer encephalitis virus (transmitted by I. persulcatus).[6][7]

Russia and Europe report about 5,000–7,000 human cases annually.[1][8]

The former Soviet Union conducted research on tick-borne diseases, including the TBE viruses.


Sheep ticks (Ixodes ricinus), such as this engorged female, transmit the disease

It is transmitted by the bite of several species of infected woodland ticks, including Ixodes scapularis, I. ricinus and I. persulcatus,[9] or (rarely) through the non-pasteurized milk of infected cows.[10]

Infection acquired through goat milk consumed as raw milk or raw cheese (Frischkäse) has been documented in 2016 and 2017 in the German state of Baden-Württemberg. None of the infected had neurological disease.[11]


Detection of specific IgM and IgG antibodies in patients sera combined with typical clinical signs, is the principal method for diagnosis. In more complicated situations, e.g. after vaccination, testing for presence of antibodies in cerebrospinal fluid may be necessary [12].

PCR (Polymerase Chain Reaction) method is rarely used, since TBE virus RNA is most often not present in patient sera or cerebrospinal fluid at the time of clinical symptoms.


A sign in Lithuanian forest, warning about a high probability to be infected by tick-borne encephalitis

Prevention includes non-specific (tick-bite prevention, tick checks) and specific prophylaxis in the form of a vaccination. Tick-borne encephalitis vaccines are very effective and available in many disease endemic areas and in travel clinics.[13] Trade names are Encepur N[14] and FSME-Immun CC.[15]


There is no specific antiviral treatment for TBE. Symptomatic brain damage requires hospitalization and supportive care based on syndrome severity. Anti-inflammatory drugs, such as corticosteroids, may be considered under specific circumstances for symptomatic relief. Tracheal intubation and respiratory support may be necessary.


As of 2011, the disease was most common in Central and Eastern Europe, and Northern Asia. About ten to twelve thousand cases are documented a year but the rates vary widely from one region to another.[16] Most of the variation has been the result of variation in host population, particularly that of deer. In Austria, an extensive free vaccination program since the 1960s reduced the incidence in 2013 by roughly 85%.[17]

In Germany, during the 2010s, there have been a minimum of 95 (2012) and a maximum of 584 cases (2018) of TBE (or FSME as it is known in German). More than half of the reported cases from 2019 had meningitis, encephalitis or myelitis. The risk of infection was noted to be increasing with age, especially in people older than 40 years and it was greater in men than women. Most cases were acquired in Bavaria (46 %) and Baden-Württemberg (37%), much less in Saxonia, Hesse, Niedersachsen and other states. Altogether 164 Landkreise are designated FSME-risk areas, including all of Baden-Württemberg except for the city of Heilbronn.[11]

In Sweden, most cases of TBE occur in a band running from Stockholm to the west, especially around lakes and the nearby region of the Baltic sea.[18][19] It reflects the greater population involved in outdoor activities in these areas. Overall, for Europe, the estimated risk is roughly 1 case per 10,000 human-months of woodland activity. Although in some regions of Russia and Slovenia, the prevalence of cases can be as high as 70 cases per 100,000 people per year.[17][20] Travelers to endemic regions do not often become cases, with only 5 cases reported among U.S. travelers returning from Eurasia between 2000 and 2011, a rate so low that as of 2016 the U.S. Centers for Disease Control and Prevention recommended vaccination only for those who will be extensively exposed in high risk areas.[21]


  1. ^ a b Suss J (June 2008). "Tick-borne encephalitis in Europe and beyond--the epidemiological situation as of 2007". Euro Surveill. 13 (26). PMID 18761916.
  2. ^ "Factsheet about tick-borne encephalitis (TBE)". European Centre for Disease Prevention and Control. Retrieved 15 January 2019.
  3. ^ a b c Tickborne Encephalitis Virus reviewed and published by WikiVet, accessed 12 October 2011.
  4. ^ Riccardi N (22 January 2019). "Tick-borne encephalitis in Europe: a brief update on epidemiology, diagnosis, prevention, and treatment". Eur J Intern Med. 62: 1–6. doi:10.1016/j.ejim.2019.01.004. PMID 30678880.
  5. ^ Kaiser R (September 2008). "Tick-borne encephalitis". Infect. Dis. Clin. North Am. 22 (3): 561–75, x. doi:10.1016/j.idc.2008.03.013. PMID 18755391.
  6. ^ "Factsheet about tick-borne encephalitis (TBE)". European Centre for Disease Prevention and Control. Retrieved 15 January 2019.
  7. ^ "Tick-borne Encephalitis (TBE)". Centers for Disease Control and Prevention. Retrieved 15 January 2019.
  8. ^ Salisbury, Dr David; Noakes, Dr Karen (2006). Immunisation against infectious disease (Third ed.). TSO (The Stationery Office - UK Department Of Health). pp. 385–390. ISBN 978-0-11-322528-6.
  9. ^ Dumpis U, Crook D, Oksi J (April 1999). "Tick-borne encephalitis". Clin. Infect. Dis. 28 (4): 882–90. doi:10.1086/515195. PMID 10825054.
  10. ^ CDC Yellow Book, accessed 5 October 2013.
  11. ^ a b "FSME: Risikogebiete in Deutschland" (PDF). Epidemiologisches Bulletin, RKI (in German). Berlin. 8. 2020.
  12. ^ "Factsheet about tick-borne encephalitis (TBE)". European Centre for Disease Prevention and Control. Retrieved 2018-10-18.
  13. ^ Demicheli V, Debalini MG, Rivetti A (2009). Demicheli V (ed.). "Vaccines for preventing tick-borne encephalitis". Cochrane Database Syst Rev (1): CD000977. doi:10.1002/14651858.CD000977.pub2. PMC 6532705. PMID 19160184.
  14. ^ "Encepur® N". compendium.ch. 2016-04-28. Retrieved 2018-01-21.
  15. ^ "FSME-Immun® CC". compendium.ch. 2017-08-11. Retrieved 2018-01-21.
  16. ^ "Vaccines against tick-borne encephalitis: WHO position paper" (PDF). Relevé Épidémiologique Hebdomadaire, Section d'Hygiène du Secrétariat de la Société des Nations. 86 (24): 241–56. 10 June 2011. PMID 21661276.
  17. ^ a b Amicizia, Daniela; Domnich, Alexander; Panatto, Donatella; Lai, Piero Luigi; Cristina, Maria Luisa; Avio, Ulderico; Gasparini, Roberto (2013-05-14). "Epidemiology of tick-borne encephalitis (TBE) in Europe and its prevention by available vaccines". Human Vaccines & Immunotherapeutics. 9 (5): 1163–1171. doi:10.4161/hv.23802. ISSN 2164-5515. PMC 3899155. PMID 23377671.
  18. ^ Pettersson, John H.-O.; Golovljova, Irina; Vene, Sirkka; Jaenson, Thomas G. T. (2014-01-01). "Prevalence of tick-borne encephalitis virus in Ixodes ricinus ticks in northern Europe with particular reference to Southern Sweden". Parasites & Vectors. 7: 102. doi:10.1186/1756-3305-7-102. ISSN 1756-3305. PMC 4007564. PMID 24618209.
  19. ^ team, European Centre for Disease Prevention and Control (ECDC)-Health Communication Unit- Eurosurveillance editorial (2011). "Tick-borne encephalitis increasing in Sweden, 2011". Eurosurveillance. 16 (39). doi:10.2807/ese.16.39.19981-en. PMID 21968422.
  20. ^ team, European Centre for Disease Prevention and Control (ECDC)-Health Communication Unit- Eurosurveillance editorial (2011-03-11). "Case report: Tick-borne encephalitis in two Dutch travellers returning from Austria, Netherlands, July and August 2011". Eurosurveillance. 16 (44): 20003. doi:10.2807/ese.16.44.20003-en (inactive 2020-08-24). PMID 22085619. Retrieved 2016-06-04.CS1 maint: DOI inactive as of August 2020 (link)
  21. ^ "Tickborne Encephalitis - Chapter 3 - 2016 Yellow Book | Travelers' Health | CDC". wwwnc.cdc.gov. Retrieved 2016-06-04.

External links[edit]

External resources